The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)Sandra Gottschling, Roland Penzel, Wilfried Eberhardt et al.|Lung Cancer|2012Cited by 13